Terms: = Germ cell tumor AND GNAS, RP4-543J19_4, 2778, ENSG00000087460, NESP55, NESP, GSP, POH, GNASXL, GNAS1, C20orf45, dJ309F20_1_1, SCG6, GPSA, Gnas, dJ806M20_3_3, XL2, MGC33735, XL, PHP1A, GSA, AHO, XLalphas, PHP1B AND Clinical Outcome
760 results:
1. Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial.
Li R; Li X; You X; Su M; Liu Y; Ke N; Cao D
Cancer Med; 2024 Apr; 13(8):e7131. PubMed ID: 38629255
[TBL] [Abstract] [Full Text] [Related]
2. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract] [Full Text] [Related]
3. Soft-tissue reconstruction with pedicled vertical rectus abdominis myocutaneous flap after total or high sacrectomy for giant sacral tumor.
Huang W; Hu X; Cai W; Cheng M; Fang M; Sun Z; Hu T; Yan W
J Plast Reconstr Aesthet Surg; 2024 Apr; 91():173-180. PubMed ID: 38417394
[TBL] [Abstract] [Full Text] [Related]
4. Kinome-Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in Glioblastoma.
Vella V; Ditsiou A; Chalari A; Eravci M; Wooller SK; Gagliano T; Bani C; Kerschbamer E; Karakostas C; Xu B; Zhang Y; Pearl FMG; Lopez G; Peng L; Stebbing J; Klinakis A; Giamas G
Adv Sci (Weinh); 2024 Apr; 11(15):e2306027. PubMed ID: 38353396
[TBL] [Abstract] [Full Text] [Related]
5. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation.
Liu Q; Adhikari E; Lester DK; Fang B; Johnson JO; Tian Y; Mockabee-Macias AT; Izumi V; Guzman KM; White MG; Koomen JM; Wargo JA; Messina JL; Qi J; Lau EK
Nat Commun; 2024 Feb; 15(1):1148. PubMed ID: 38326303
[TBL] [Abstract] [Full Text] [Related]
6. GammaTile
Yekula A; Gessler DJ; Ferreira C; Shah R; Reynolds M; Dusenbery K; Chen CC
J Neurooncol; 2024 Feb; 166(3):441-450. PubMed ID: 38281303
[TBL] [Abstract] [Full Text] [Related]
7. National multicentered retrospective review of clinical and intraoperative factors associated with the development of cerebellar mutism after pediatric posterior fossa tumor resection.
Kameda-Smith MM; Ragulojan M; Elliott C; Bliss L; Moore H; Sader N; Alsuwaihel M; Tso MK; Dakson A; Ajani O; Yarascavitch B; Fleming A; Mehta V; Aminnejad M; Farrokhyar F; Singh SK;
Childs Nerv Syst; 2024 May; 40(5):1339-1347. PubMed ID: 38279985
[TBL] [Abstract] [Full Text] [Related]
8. Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
Bennebroek CA; Schouten CR; Montauban-van Swijndregt MC; Saeed P; Porro GL; Pott JWR; Dittrich ATM; Oostenbrink R; Schouten-van Meeteren AY; de Jong MC; de Graaf P
J Neurooncol; 2024 Jan; 166(1):79-87. PubMed ID: 38150061
[TBL] [Abstract] [Full Text] [Related]
9. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract] [Full Text] [Related]
10. PATIENT-RELATED FACTORS AND clinical MANAGEMENT outcomeS OF RETINOBLASTOMA IN CALABAR, NIGERIA.
Nkanga ED; Nlemadim AC; Arazi M; Nkanga DG; Duke RE; Fabian ID; Nkanga ED; Odey FA; Meremikwu MM
West Afr J Med; 2023 Dec; 40(12 Suppl 1):S36-S37. PubMed ID: 38070170
[TBL] [Abstract] [Full Text] [Related]
11. Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
Gambichler T; Iordanou M; Becker JC; Susok L
Melanoma Res; 2024 Feb; 34(1):80-83. PubMed ID: 37924529
[TBL] [Abstract] [Full Text] [Related]
12. CD8+CD103+PD1+TIM3+ T cells in glioblastoma microenvironment correlate with prognosis.
Romagnoli G; D'Alessandris QG; Capone I; Tavilla A; Canini I; Lapenta C; Buccarelli M; Giordano M; Tirelli V; Sanchez M; Fragale A; Giannetti S; Di Bonaventura R; Lauretti L; Biffoni M; Ricci-Vitiani L; Pallini R; Gabriele L
Immunology; 2024 Feb; 171(2):198-211. PubMed ID: 37884280
[TBL] [Abstract] [Full Text] [Related]
13. Molecular and clinicopathological implications of PRAME expression in adult glioma.
Le MK; Vuong HG; Dunn IF; Kondo T
PLoS One; 2023; 18(10):e0290542. PubMed ID: 37796789
[TBL] [Abstract] [Full Text] [Related]
14. Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
[TBL] [Abstract] [Full Text] [Related]
15. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract] [Full Text] [Related]
16. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
17. Association of clinical manifestations of secondary lymphedema and lymph node dissection sites in the lower extremities of patients with melanoma.
Chae Woon P; Kim I; Kim JH; Hwang JH
Acta Oncol; 2023 Aug; 62(8):880-888. PubMed ID: 37656769
[TBL] [Abstract] [Full Text] [Related]
18. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
19. Adrenal and periadrenal schwannoma: histological, molecular and clinical characterization of an institutional case series.
Stenman A; Falhammar H; Zedenius J; Juhlin CC
Endocrine; 2023 Dec; 82(3):631-637. PubMed ID: 37535242
[TBL] [Abstract] [Full Text] [Related]
20. clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.
Kolodziejczak AS; Guerrini-Rousseau L; Planchon JM; Ecker J; Selt F; Mynarek M; Obrecht D; Sill M; Autry RJ; Stutheit-Zhao E; Hirsch S; Amouyal E; Dufour C; Ayrault O; Torrejon J; Waszak SM; Ramaswamy V; Pentikainen V; Demir HA; Clifford SC; Schwalbe EC; Massimi L; Snuderl M; Galbraith K; Karajannis MA; Hill K; Li BK; Walsh M; White CL; Redmond S; Loizos L; Jakob M; Kordes UR; Schmid I; Hauer J; Blattmann C; Filippidou M; Piccolo G; Scheurlen W; Farrag A; Grund K; Sutter C; Pietsch T; Frank S; Schewe DM; Malkin D; Ben-Arush M; Sehested A; Wong TT; Wu KS; Liu YL; Carceller F; Mueller S; Stoller S; Taylor MD; Tabori U; Bouffet E; Kool M; Sahm F; von Deimling A; Korshunov A; von Hoff K; Kratz CP; Sturm D; Jones DTW; Rutkowski S; van Tilburg CM; Witt O; Bougeard G; Pajtler KW; Pfister SM; Bourdeaut F; Milde T
Neuro Oncol; 2023 Dec; 25(12):2273-2286. PubMed ID: 37379234
[TBL] [Abstract] [Full Text] [Related]
[Next]
